SJFα

Target: SJFα selectively targets p38α MAP kinase, with weaker activity toward p38δ.

Binding site: Its foretinib-derived ligand engages the ATP-binding catalytic pocket of p38α.

Mechanism of action: SJFα is a VHL-based PROTAC that links a foretinib-derived kinase ligand to a von Hippel-Lindau E3 ligase ligand through a defined linker architecture. This design preferentially recruits p38α MAP kinase into a productive ternary complex with VHL, enabling ubiquitination and proteasome-mediated degradation. Compared with broad kinase inhibition, SJFα provides a degradation-based tool for examining p38α-specific signaling contributions while minimizing degradation of p38β, p38γ, ERK, or JNK family members. It is useful for pathway-dissection studies requiring selective depletion of p38α protein.

• PROTAC-Mediated Protein Degradation: SJFα is utilized in research to explore the targeted degradation of specific proteins, enabling the study of protein function and cellular processes. This application aids in dissecting complex biological pathways by selectively removing proteins of interest, offering insights into their roles in disease mechanisms.

• Targeted Degradation in Cancer Research: Researchers employ SJFα to investigate the degradation of oncogenic proteins, facilitating the study of cancer biology. By eliminating proteins that drive tumor growth, SJFα assists in identifying new therapeutic targets and understanding the molecular underpinnings of cancer progression.

• Degradation Pathway Elucidation: SJFα is instrumental in elucidating the mechanisms of the ubiquitin-proteasome system. By targeting proteins for degradation, it allows scientists to map the pathways and interactions involved in protein turnover, advancing knowledge of cellular homeostasis and protein lifecycle management.

• Drug Discovery and Development: In the context of drug discovery, SJFα serves as a tool for validating potential drug targets through PROTAC-mediated degradation. This application supports the identification of novel drug candidates by confirming the functional relevance of target proteins in disease models.